SAB Biotherapeutics (SABS) Long-Term Investments (2021 - 2026)

SAB Biotherapeutics has reported Long-Term Investments for 4 years, with the latest figure at $110.2 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments changed N/A year-over-year to $110.2 million; the trailing twelve-month figure through Mar 2026 stood at $110.2 million (changed N/A YoY), and the FY2025 full-year result was $46.9 million, changed N/A from the prior year.
• Long-Term Investments for Q1 2026 stood at $110.2 million, up from $46.9 million in the prior quarter.
• The five-year high for Long-Term Investments was $110.2 million in Q1 2026, with the low at $1.2 million in Q1 2024.
• Historically, Long-Term Investments has averaged $52.2 million across 3 years, with a median of $48.8 million in 2025.